MCID: MLG169
MIFTS: 47

Malignant Astrocytoma

Categories: Cancer diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Malignant Astrocytoma

MalaCards integrated aliases for Malignant Astrocytoma:

Name: Malignant Astrocytoma 11 75 5 14
Astrocytoma of Cerebrum 11
Astrocytoma of Brain 11
Cerebral Astrocytoma 11
Astrocytic Tumor 11
Astroglioma 11
Astrocytoma 43

Classifications:



External Ids:

Disease Ontology 11 DOID:3069
MeSH 43 D001254
NCIt 49 C4951 C60781
UMLS 71 C0004114 C0750935

Summaries for Malignant Astrocytoma

Disease Ontology: 11 A malignant glioma that is has material basis in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord.

MalaCards based summary: Malignant Astrocytoma, also known as astrocytoma of cerebrum, is related to anaplastic astrocytoma and idh-mutant anaplastic astrocytoma. An important gene associated with Malignant Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are miRNAs involved in DNA damage response and miRNAs involvement in the immune response in sepsis. The drugs Dabrafenib and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone marrow.

Wikipedia: 75 Astrocytomas are a type of brain tumor. They originate in a particular kind of glial cells, star-shaped... more...

Related Diseases for Malignant Astrocytoma

Diseases related to Malignant Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1053)
# Related Disease Score Top Affiliating Genes
1 anaplastic astrocytoma 32.8 TP53 MIR196A1 KDM4C H2AC18 ATRX
2 idh-mutant anaplastic astrocytoma 32.7 KDM4C ATRX
3 mixed oligodendroglioma-astrocytoma 32.3 TP53 ATRX
4 glioblastoma 32.3 TP53 MIR221 MIR21 MIR155 DGCR5 AGAP2-AS1
5 adult astrocytic tumor 32.2 TP53 ATRX
6 glioma susceptibility 1 32.2 TP53 MIR21 DGCR5
7 brain cancer 31.9 TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
8 high grade glioma 31.8 TPT1-AS1 TP53 MIR9-1 MIR338 MIR221 MIR21
9 central nervous system cancer 31.4 TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
10 glioma 31.3 TP53 MIR221 MIR21 MIR17
11 high-grade astrocytoma 31.3 TP53 ATRX
12 retinal cancer 31.2 TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
13 medulloblastoma 31.2 TP53 NEURL1 MIR9-1 MIR221 MIR17 MIR155
14 lung cancer 31.1 TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
15 peripheral nervous system disease 31.1 TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR196A1
16 respiratory failure 31.1 MIR21 MIR199A1 MIR17 MIR155 MIR142 H2AC18
17 anaplastic oligodendroglioma 31.1 TP53 KDM4C ATRX
18 diffuse astrocytoma 31.1 TP53 KDM4C H2AC18 ATRX
19 demyelinating disease 31.0 MIR9-1 MIR338 MIR21 MIR155 MIR142 MIR124-1
20 leukemia, chronic myeloid 31.0 TP53 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR155
21 toxic encephalopathy 31.0 TP53 MIR9-1 MIR142 MIR124-1 H2AC18
22 parkinson disease, late-onset 31.0 NEDD8 MIR9-1 MIR21 MIR155 MIR142 MIR124-1
23 spinal cord disease 31.0 TP53 MIR9-1 MIR199A1 MIR196A1 MIR155 MIR142
24 myelodysplastic syndrome 31.0 TP53 MIR9-1 MIR221 MIR199A1 MIR17 MIR142
25 focal epilepsy 30.9 MIR9-1 MIR21 MIR142 MIR124-1
26 leukemia, acute myeloid 30.9 TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
27 leukemia, acute lymphoblastic 30.9 TP53 MIR9-1 MIR221 MIR21 MIR199A1 MIR196A1
28 low grade glioma 30.9 TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR155
29 bone disease 30.9 MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
30 nervous system disease 30.8 TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
31 myeloma, multiple 30.8 TP53 MIR9-1 MIR221 MIR21 MIR199A1 MIR17
32 immune deficiency disease 30.8 MIR9-1 MIR221 MIR21 MIR199A1 MIR196A1 MIR17
33 lung cancer susceptibility 3 30.8 TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR196A1
34 melanoma, uveal 30.8 TP53 MIR9-1 MIR199A1 MIR17 MIR142 KDM4C
35 cerebellar disease 30.8 TP53 MIR9-1 KDM4C H2AC18
36 alzheimer disease, familial, 1 30.8 MIR9-1 MIR338 MIR21 MIR199A1 MIR17 MIR142
37 acute promyelocytic leukemia 30.8 TP53 MIR9-1 MIR221 MIR196A1 MIR17 KDM4C
38 renal cell carcinoma, nonpapillary 30.8 TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
39 diffuse midline glioma, h3 k27m-mutant 30.8 TP53 H2AC18 ATRX
40 central nervous system disease 30.8 MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
41 hematologic cancer 30.8 MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
42 ovarian cancer 30.8 TP53 MIR9-1 MIR221 MIR21 MIR199A1 MIR196A1
43 brain glioma 30.8 TP53 KDM4C H2AC18 DGCR5 ATRX
44 nasopharyngeal carcinoma 30.8 TP53 MIR9-1 MIR338 MIR21 MIR196A1 MIR17
45 t-cell acute lymphoblastic leukemia 30.8 MIR9-1 MIR17 MIR155 MIR142 KDM4C H2AC18
46 viral infectious disease 30.8 MIR21 MIR199A1 MIR155 H2AC18
47 oral squamous cell carcinoma 30.8 MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
48 atypical teratoid rhabdoid tumor 30.7 TP53 MIR142 MIR124-1 H2AC18 ATRX
49 cerebrovascular disease 30.7 MIR9-1 MIR221 MIR21 MIR199A1 MIR17 MIR155
50 skin melanoma 30.7 TP53 MIR21 MIR199A1 KDM4C H2AC18

Graphical network of the top 20 diseases related to Malignant Astrocytoma:



Diseases related to Malignant Astrocytoma

Symptoms & Phenotypes for Malignant Astrocytoma

Drugs & Therapeutics for Malignant Astrocytoma

Drugs for Malignant Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 262)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
2
Tranexamic acid Approved Phase 3 1197-18-8 5526
3
Carmustine Approved, Investigational Phase 3 154-93-8 2578
4
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
5
Tioguanine Approved Phase 3 154-42-7 2723601
6
Hydroxyurea Approved Phase 3 127-07-1 3657
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Vinblastine Approved Phase 3 865-21-4 241903 13342
9
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
10
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
11
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
12
Eflornithine Approved, Withdrawn Phase 3 70052-12-9 3009
13
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
14
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
15
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
16
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
17
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
18
Semustine Experimental, Investigational Phase 3 13909-09-6 5198
19
Trabedersen Investigational Phase 3 925681-61-4
20 Antifibrinolytic Agents Phase 3
21 Hemostatics Phase 3
22 Coagulants Phase 3
23
Imatinib Mesylate Phase 3 220127-57-1
24 Antimitotic Agents Phase 3
25 Tubulin Modulators Phase 3
26 Anticonvulsants Phase 3
27 Psychotropic Drugs Phase 3
28 Endothelial Growth Factors Phase 2, Phase 3
29 Vaccines Phase 3
30 Angiogenesis Inhibitors Phase 2, Phase 3
31 Antineoplastic Agents, Immunological Phase 2, Phase 3
32 Mitogens Phase 3
33
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
36
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
37
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
38
Melphalan Approved Phase 2 148-82-3 4053 460612
39
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
40
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
41
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
42
Lapatinib Approved, Investigational Phase 1, Phase 2 231277-92-2, 388082-78-8 208908
43
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
44
Iodine Approved, Investigational Phase 2 7553-56-2 807
45
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
48
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
49
Aflibercept Approved Phase 2 862111-32-8 124490314
50
Thiotepa Approved, Investigational Phase 2 52-24-4 5453

Interventional clinical trials:

(show top 50) (show all 360)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
3 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
4 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
5 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
6 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
7 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
8 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
9 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
10 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
11 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
12 A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC) Completed NCT00789828 Phase 3 Everolimus;Placebo
13 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
14 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
15 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
16 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
17 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
18 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
19 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
20 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Active, not recruiting NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
21 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Active, not recruiting NCT02796261 Phase 3 Eflornithine;Lomustine
22 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Active, not recruiting NCT00045968 Phase 3 Dendritic cell immunotherapy
23 Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
24 A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Terminated NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
25 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
26 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Withdrawn NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
27 A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
28 Pediatric Low Grade Astrocytoma: Treatment Guidance Unknown status NCT00005084 Phase 2
29 A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
30 A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas Unknown status NCT02209428 Phase 2 Temozolomide
31 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
32 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
33 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
34 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma Completed NCT00679354 Phase 2 cilengitide
35 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
36 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
37 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
38 Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Completed NCT02942264 Phase 1, Phase 2 Zotiraciclib (TG02);Temozolomide (TMZ)
39 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
40 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
41 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
42 Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma) Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
43 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
44 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 Everolimus
45 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
46 Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas Completed NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
47 SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma Completed NCT00783393 Phase 2 Temozolomide
48 A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma Completed NCT00409214 Phase 2 LS11 (talaporfin sodium)
49 Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma) Completed NCT00014170 Phase 2 gefitinib
50 A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide

Search NIH Clinical Center for Malignant Astrocytoma

Cochrane evidence based reviews: astrocytoma

Genetic Tests for Malignant Astrocytoma

Anatomical Context for Malignant Astrocytoma

Organs/tissues related to Malignant Astrocytoma:

MalaCards : Brain, Spinal Cord, Bone Marrow, Breast, Endothelial, Bone, Cerebellum

Publications for Malignant Astrocytoma

Articles related to Malignant Astrocytoma:

(show top 50) (show all 1100)
# Title Authors PMID Year
1
Lateralized overgrowth with vascular malformation caused by a somatic PTPN11 pathogenic variant: Another piece added to the puzzle of mosaic RASopathies. 62
35778969 2022
2
Graphene oxide induced dynamic changes of autophagy-lysosome pathway and cell apoptosis via TFEB dysregulation in F98 cells. 62
36244172 2022
3
GDNF Promotes Astrocyte Abnormal Proliferation and Migration Through the GFRα1/RET/MAPK/pCREB/LOXL2 Signaling Axis. 62
35925441 2022
4
Malignant transformation in low-grade astrocytoma for long-term monitoring. 62
36412420 2022
5
Clinicopathological analysis of secondary retinal vasoproliferative tumor/reactive retinal astrocytic tumor successfully treated by endoresection. 62
36067444 2022
6
Lateral ventricle pleomorphic xanthoastrocytoma concurrent with Dandy-Walker complex: A case report. 62
36086683 2022
7
The imaging of the hypoxic microenvironment in tumorous tissue using PET/CT and PET/MRI. 62
35926354 2022
8
Circular RNA circPOSTN promotes neovascularization by regulating miR-219a-2-3p/STC1 axis and stimulating the secretion of VEGFA in glioblastoma. 62
35927233 2022
9
GLIPR1 regulates the TIMP1-CD63-ITGB1-AKT signaling pathway in glioma cells and induces malignant transformation of astroglioma. 62
35966296 2022
10
Global variation in young adult central nervous system tumor incidence by region, age, and sex from 1988 to 2012. 62
35395483 2022
11
Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis. 62
35873847 2022
12
The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma. 62
35570844 2022
13
GFAPδ: A Promising Biomarker and Therapeutic Target in Glioblastoma. 62
35372061 2022
14
Molecular Signaling and Transcriptional Regulation of Histamine H1 Receptor Gene. 62
34595742 2022
15
Circular RNA NF1-419 Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells. 62
34376137 2022
16
Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies. 62
34293392 2021
17
Photosensitizer IR700DX-6T- and IR700DX-mbc94-mediated photodynamic therapy markedly elicits anticancer immune responses during treatment of pancreatic cancer. 62
34390852 2021
18
Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis. 62
35071077 2021
19
Atomic Force Microscope Nanoindentation Analysis of Diffuse Astrocytic Tumor Elasticity: Relation with Tumor Histopathology. 62
34572766 2021
20
4-Methoxydalbergione is a potent inhibitor of human astroglioma U87 cells in vitro and in vivo. 62
33311599 2021
21
The histological representativeness of glioblastoma tissue samples. 62
33085022 2021
22
Plasma lipidome is dysregulated in Alzheimer's disease and is associated with disease risk genes. 62
34092785 2021
23
Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts. 62
33685995 2021
24
Zika virus dysregulates the expression of astrocytic genes involved in neurodevelopment. 62
33891593 2021
25
Molecular Mechanism of Vitamin K2 Protection against Amyloid-β-Induced Cytotoxicity. 62
33805625 2021
26
Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP/PS1 mice. 62
33300068 2021
27
4-Methoxydalbergione Inhibits Bladder Cancer Cell Growth via Inducing Autophagy and Inhibiting Akt/ERK Signaling Pathway. 62
35252345 2021
28
Theabrownin Induces Cell Apoptosis and Cell Cycle Arrest of Oligodendroglioma and Astrocytoma in Different Pathways. 62
33995088 2021
29
Manipulations of Glutathione Metabolism Modulate IP3-Mediated Store-Operated Ca2+ Entry on Astroglioma Cell Line. 62
34975458 2021
30
The Glutathione Metabolite γ-Glutamyl-Glutamate Partially Activates Glutamate NMDA Receptors in Central Neurons With Higher Efficacy for GluN2B-Containing Receptors. 62
35046818 2021
31
Malignant transformation of pleomorphic xanthoastrocytoma in pregnant patient: Clinical case and ethical dilemma. 62
34621584 2021
32
Long-term survival of a patient with diffuse midline glioma in the pineal region: A case report and literature review. 62
34992928 2021
33
β2-Adrenergic Receptor Stimulation Upregulates Cx43 Expression on Glioblastoma Multiforme and Olfactory Ensheathing Cells. 62
32506304 2020
34
Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53. 62
33086722 2020
35
[Diffuse Astrocytoma with Malignant Progression after Long-term Temozolomide Monotherapy:A Case Report]. 62
33071231 2020
36
Gamma-Linolenic acid alters migration, proliferation and apoptosis in human and rat glioblastoma cells. 62
32439412 2020
37
Optic nerve head reactive retinal astrocytic tumor treated with photodynamic therapy. 62
32715158 2020
38
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. 62
32064499 2020
39
Reactivation of Retinopathy of Prematurity in Adults and Adolescents. 62
32224099 2020
40
Beclin1 Binds to Enterovirus 71 3D Protein to Promote the Virus Replication. 62
32674313 2020
41
Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature. 62
31986557 2020
42
Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival. 62
31677196 2020
43
Arsenic trioxide induces gasdermin E mediated pyroptosis in astroglioma cells. 62
35117539 2020
44
The interrupted effect of autophagic flux and lysosomal function induced by graphene oxide in p62-dependent apoptosis of F98 cells. 62
32188458 2020
45
MiR-1247-5p Functions as a Tumor Suppressor in Human Astroglioma Cells by Targeting CDC14B. 62
32366555 2020
46
Glyphosate-based herbicide impairs energy metabolism and increases autophagy in C6 astroglioma cell line. 62
32085696 2020
47
Nifurtimox Hampered the Progression of Astroglioma In vivo Via Manipulating the AKT-GSK3β axis. 62
32271693 2020
48
Splice-site variant in ACSL5: a marker promoting opposing effect on cell viability and protein expression. 62
31053784 2019
49
Retinal vasoproliferative tumor (Retinal reactive astrocytic tumor). 62
31296349 2019
50
Cytotoxic and apoptotic potential of Phyllodium elegans extracts on human cancer cell lines. 62
31633448 2019

Variations for Malignant Astrocytoma

ClinVar genetic disease variations for Malignant Astrocytoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Pathogenic
12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
2 ATRX NM_000489.6(ATRX):c.5579A>G (p.Asn1860Ser) SNV Pathogenic
11724 rs45439799 GRCh37: X:76856021-76856021
GRCh38: X:77600552-77600552
3 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Pathogenic
12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776

Expression for Malignant Astrocytoma

Search GEO for disease gene expression data for Malignant Astrocytoma.

Pathways for Malignant Astrocytoma

Pathways related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.28 TP53 MIR221 MIR21 MIR17
2 11.05 MIR9-1 MIR21 MIR199A1 MIR155
3
Show member pathways
10.92 MIR9-1 MIR221 MIR199A1 MIR17 MIR155

GO Terms for Malignant Astrocytoma

Cellular components related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.62 MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1

Biological processes related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.63 MIR221 MIR21 MIR17
2 miRNA-mediated gene silencing GO:0035195 9.58 MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
3 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.5 MIR221 MIR199A1 MIR196A1
4 negative regulation of gene expression GO:0010629 9.5 MIR155 MIR17 MIR199A1 MIR21 MIR338 MIR9-1
5 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.46 MIR9-1 MIR221 MIR21 MIR17
6 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.43 MIR199A1 MIR17
7 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.4 MIR21 MIR17
8 positive regulation of metalloendopeptidase activity GO:1904685 9.37 MIR21 MIR17
9 negative regulation of interleukin-21 production GO:0032705 9.26 MIR221 MIR21

Molecular functions related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.61 TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR17
2 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1

Sources for Malignant Astrocytoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....